Literature DB >> 24444440

Apolipoprotein B of low-density lipoprotein impairs nitric oxide-mediated endothelium-dependent relaxation in rat mesenteric arteries.

Yaping Zhang1, Wei Zhang2, Lars Edvinsson3, Cang-Bao Xu4.   

Abstract

Apolipoprotein B (ApoB) of low-density lipoprotein (LDL) causes endothelial dysfunction in the initial stage of atherogenesis. The present study was designed to explore the underlying molecular mechanisms involved. Rat mesenteric arteries were organ cultured in the presence of different concentrations of ApoB or LDL. Vasodilation induced by acetylcholine was monitored by a sensitive myograph. Nitric oxide (NO), endothelium-dependent hyperpolarizing factor (EDHF) and prostacyclin (PGI2) pathways were characterized by using specific pathway inhibitors. Real-time PCR and immunohistochemistry with confocal microscopy were used to examine alteration of mRNA and protein expressions for NO synthases (eNOS and iNOS) and cycloxygenase (COX), respectively. Lipid peroxidation was measured by thiobarbituric acid reactive substances. In the presence of either LDL or ApoB for 24h concentration-dependently attenuated the endothelium-dependent vasodilation. Immunohistochemistry staining of endothelial cell marker CD31 was weaker in the presence of LDL, indicating that LDL induced damage to the endothelium. Using the pathway specific inhibitors demonstrated that LDL-induced impairing vasodilation was mainly due to attenuation of NO pathway. This was supported by decreasing mRNA (real-time PCR) and protein expression (immunohistochemistry) for eNOS and iNOS, but not COX, in the presence of LDL. In addition, the levels of lipid peroxidation significantly increased in the presence of LDL for 24h. In conclusion, ApoB of LDL impairs vasodilation with damaging the endothelium and attenuating the NO-mediated endothelium-dependent relaxation, which might associate with lipid peroxidation and contribute to the development of cardiovascular disease.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-hydroxytryptamine (PubChem CID: 5202); Acetylcholine (PubChem CID: 187); Apolipoprotein B; Cardiovascular disease; Endothelial dysfunction; Lipid peroxidation; Low-density lipoprotein; N(ω)-nitro-l-arginine methyl ester (PubChem CID: 39836); Vasodilation; apamin (PubChem CID: 16129677); charybdotoxin (PubChem CID: 56842037); indomethacin (PubChem CID: 3715)

Mesh:

Substances:

Year:  2014        PMID: 24444440     DOI: 10.1016/j.ejphar.2014.01.008

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  GPR55 agonist lysophosphatidylinositol and lysophosphatidylcholine inhibit endothelial cell hyperpolarization via GPR-independent suppression of Na+-Ca2+ exchanger and endoplasmic reticulum Ca2+ refilling.

Authors:  Alexander I Bondarenko; Fabrizio Montecucco; Olga Panasiuk; Vadim Sagach; Nataliya Sidoryak; Karim J Brandt; François Mach
Journal:  Vascul Pharmacol       Date:  2017-01-05       Impact factor: 5.773

2.  Pretreatment with β-Boswellic Acid Improves Blood Stasis Induced Endothelial Dysfunction: Role of eNOS Activation.

Authors:  Mingming Wang; Minchun Chen; Yi Ding; Zhihui Zhu; Yikai Zhang; Peifeng Wei; Jingwen Wang; Yi Qiao; Liang Li; Yuwen Li; Aidong Wen
Journal:  Sci Rep       Date:  2015-10-20       Impact factor: 4.379

Review 3.  Neuroprotective Properties of Linagliptin: Focus on Biochemical Mechanisms in Cerebral Ischemia, Vascular Dysfunction and Certain Neurodegenerative Diseases.

Authors:  Michał Wiciński; Karol Górski; Maciej Walczak; Eryk Wódkiewicz; Maciej Słupski; Katarzyna Pawlak-Osińska; Bartosz Malinowski
Journal:  Int J Mol Sci       Date:  2019-08-20       Impact factor: 5.923

4.  Enhanced Endothelin A and B Receptor Expression and Receptor-Mediated Vasoconstriction in Rat Mesenteric arteries after Lipopolysaccharide Challenge.

Authors:  Wei Zhang; Shan-Shan Zhang; Hong-Lang Huang; Bing-Jie Song; Xiao Liu; Zhi Qi
Journal:  Mediators Inflamm       Date:  2019-11-14       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.